tapotoclax

Mcl-1 Antagonist

Also Known As:

(3'R,4S,6'R,7'S,8'E,11'S,12'R)-7-chloro-7'-methoxy-11',12'-dimethyl-13',13'-dioxospiro(2,3-dihydro-1H-naphthalene-4,22'-20-oxa-13lambda6-thia-1,14-diazatetracyclo(14.7.2.03,6.019,24)pentacosa-8,16(25),17,19(24)-tetraene)-15'-one; AMG-176; AMG176

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        tapotoclax: 6
    - Spiro Compounds: 2
      - tapotoclax: 6
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - tapotoclax: 6
- Spiro Compounds: 2
  - tapotoclax: 6

Experts

1.	Gandhi, Varsha: 2 articles (01/2022 - 01/2020)
2.	Iles, LaKesla R: 2 articles (01/2022 - 01/2020)
3.	Wierda, William G: 2 articles (01/2022 - 01/2020)
4.	Yi, Xue: 2 articles (01/2022 - 01/2020)
5.	Andreeff, Michael: 1 article (01/2022)
6.	Ayres, Mary L: 1 article (01/2022)
7.	Battula, Venkata L: 1 article (01/2022)
8.	Carter, Bing Z: 1 article (01/2022)
9.	Chen, Xiaoyue: 1 article (01/2022)
10.	Hughes, Paul E: 1 article (01/2022)

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2020 - "AMG-176 is a selective and direct antagonist of Mcl-1, which has shown efficacy in several hematologic malignancies; however, its effect on CLL is elusive. " 01/01/2023 - "Several MCL-1 inhibitors (MCL-1i), including AMG-176 and AZD5991, have shown promise in preclinical studies and are being tested for the treatment of hematologic malignancies. "
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/2020 - "AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia." 01/01/2022 - "Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia."
3.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2023 - "AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas."
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2022 - "We, here, demonstrate the ineffectiveness of MCL-1 inhibitor AMG176 in venetoclax-resistant, and conversely, of venetoclax in AMG176-resistant acute myelogenous leukemia (AML). "
5.	Trisomy (Trisomies) 01/01/2021 - "We tested venetoclax in trisomy 12 CLL cells either silenced or not for Notch2 expression or in combination with an inhibitor of Mcl-1, AMG-176. "

Related Drugs and Biologics

1.	AZD5991
2.	venetoclax
3.	ibrutinib

Related Therapies and Procedures

1.	Therapeutics